<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02605967</url>
  </required_header>
  <id_info>
    <org_study_id>CPDR001X2201</org_study_id>
    <nct_id>NCT02605967</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Phase II, Open-label, Randomized Controlled Study of PDR001 in Patients With Moderately Differentiated/Undifferentiated Locally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma Who Progressed on Standard Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized controlled Phase II study is to assess the efficacy of PDR001&#xD;
      versus investigator's choice of chemotherapy in patients with advanced NPC.&#xD;
&#xD;
      By blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2, PDR001 leads to the&#xD;
      activation of a T cell mediated antitumor immune response&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 20, 2016</start_date>
  <completion_date type="Actual">February 19, 2021</completion_date>
  <primary_completion_date type="Actual">November 5, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Number of Participants with Progression Free Survival at 2 years, as per RECIST v1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival - Median PFS</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>evaluate the anti-tumor activity of PDR001 versus investigator choice of chemotherapy in NPC patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Serum Pharmacokinetics (PK) Parameters</measure>
    <time_frame>1 year</time_frame>
    <description>characterize the pharmacokinetics profiles of PDR001; PK parameters area under the curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence and /or Concentration of Anti-PDR001 Antibodies</measure>
    <time_frame>1 year</time_frame>
    <description>Assess immunogenicity serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>1 year</time_frame>
    <description>evaluate the anti-tumor activity of PDR001 versus investigator choice of chemotherapy in NPC patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>1 year</time_frame>
    <description>evaluate the anti-tumor activity of PDR001 versus investigator choice of chemotherapy in NPC patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>1 year</time_frame>
    <description>evaluate the anti-tumor activity of PDR001 versus investigator choice of chemotherapy in NPC patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Related Progression Free Survival (irPFS) Using Central Assessment</measure>
    <time_frame>2 years</time_frame>
    <description>evaluate the anti-tumor activity of PDR001 versus investigator choice of chemotherapy in NPC patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration vs.Time Profiles</measure>
    <time_frame>1 year</time_frame>
    <description>serum concentration of PDR001 on D1,D8,D15,D29,D36,D43,D57,D58,D64,D71,D85,D140</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential Associations Between Expression of PD-L1, CD8 and Other Immunological Markers With Anti-tumor Activity</measure>
    <time_frame>2 years</time_frame>
    <description>assess changes in expression of immunological markers such as CD8 and PD-L1 in tumor biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression of Immune-related Genes (RNA/Protein in Tumor Sample</measure>
    <time_frame>2 years</time_frame>
    <description>assess changes in immune-related gene signature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral, Soluble Ligands and Cytokine Levels</measure>
    <time_frame>2 years</time_frame>
    <description>assess plasma concentration levels of cytokines interferon-gamma ( IFN-γ) in pg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Serum Pharmacokinetics (PK) Parameters</measure>
    <time_frame>1 year</time_frame>
    <description>characterize the pharmacokinetics profiles of PDR001; PK parameters maximum plasma concentration(Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Serum Pharmacokinetics (PK) Parameters</measure>
    <time_frame>1 year</time_frame>
    <description>characterize the pharmacokinetics profiles of PDR001; PK parameter as the time to reach maximum peak plasma (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Serum Pharmacokinetics (PK) Parameters</measure>
    <time_frame>1 year</time_frame>
    <description>characterize the pharmacokinetics profiles of PDR001; PK parameters include the elimination half-life (T1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral, Soluble Ligands and Cytokine Levels</measure>
    <time_frame>2 years</time_frame>
    <description>assess plasma concentration levels of cytokines as tumor necrosis factor-alpha (TNF-α) in pg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral, Soluble Ligands and Cytokine Levels</measure>
    <time_frame>2 years</time_frame>
    <description>assess plasma concentration levels of cytokines as Interleukin-6 ( IL-6) in pg/ml</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>PDR001 - Investigational drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>anti-PD1 humanized monoclonal antibody</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>commonly used chemotherapy as per investigator's choice</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <description>PDR001 is a humanized anti-PD-1 IgG4 antibody which blocks the binding of PD1 to its ligands PD-L1 and PD-L2.</description>
    <arm_group_label>PDR001 - Investigational drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Investigator choice of chemotherapy</intervention_name>
    <description>commonly used chemotherapy as per investigator's choice</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically documented non-keratinizing locally advanced recurrent or metastatic&#xD;
             NPC.&#xD;
&#xD;
          -  Must be resistant to platinum-based chemotherapy (defined as progression on or after&#xD;
             platinum-based chemotherapy given in the recurrent/metastatic setting).&#xD;
&#xD;
          -  May have received at least 1 prior therapy for recurrent or metastatic disease, up to&#xD;
             2 prior systemic therapies.&#xD;
&#xD;
          -  An archival tumor specimen or newly obtained tumor sample may be submitted at&#xD;
             screening/baseline (a fresh tumor sample is preferred), unless agreed differently&#xD;
             between Novartis and the Investigator.&#xD;
&#xD;
          -  At least 1 measurable lesion (as per RECIST v1.1) progressing or new since last&#xD;
             anti-tumor therapy.&#xD;
&#xD;
          -  Prior treated brain or meningeal metastases must be without MRI evidence of&#xD;
             progression for at least 8 weeks and off systemic steroids for at least 2 weeks prior&#xD;
             to screening/baseline.&#xD;
&#xD;
          -  Patient must be willing to undergo testing for human immunodeficiency virus (HIV) if&#xD;
             not tested within the past 6 months. If HIV+ positive, patient will be eligible if:&#xD;
             his/ her CD4+ count ≥ 300/μL; his/her viral load is undetectable; he/she is currently&#xD;
             receiving highly active antiretroviral therapy (HAART).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of severe hypersensitivity reactions to other mAbs&#xD;
&#xD;
          -  Active autoimmune disease or a documented history of autoimmune disease, except&#xD;
             vitiligo or resolved asthma/atopy that is treated with broncho-dilators.&#xD;
&#xD;
          -  Active HBV or HCV infections requiring therapy.&#xD;
&#xD;
          -  Prior PD-1- or PD-L1-directed therapy or any therapeutic cancer vaccine.&#xD;
&#xD;
          -  Patients receiving systemic treatment with any immunosuppressive medication.&#xD;
&#xD;
          -  Use of any vaccines against infectious diseases (e.g. varicella, pneumococcus) within&#xD;
             4 weeks of initiation of study treatment.&#xD;
&#xD;
        Other protocol-define inclusion/exclusion may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwest Georgia Oncology Center NWGA Onc - Carrollton</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Laura and Isaac Perlmutter Cancer Center Laura &amp; Isaac Perlmutter Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nice Cedex 2</city>
        <state>Alpes Maritimes</state>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tuen Mun</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tainan</city>
        <state>Taiwan ROC</state>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taoyuan</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Songkhla</city>
        <state>Hat Yai</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>France</country>
    <country>Hong Kong</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>November 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2015</study_first_posted>
  <results_first_submitted>April 21, 2021</results_first_submitted>
  <results_first_submitted_qc>July 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 12, 2021</results_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PDR001,</keyword>
  <keyword>nasopharyngeal cancer,</keyword>
  <keyword>moderately differentiated/undifferentiated,</keyword>
  <keyword>locally advanced,</keyword>
  <keyword>recurrent or metastatic NPC,</keyword>
  <keyword>after first- line platinum-based therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spartalizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT02605967/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT02605967/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Of the 40 subjects from the chemotherapy arm, 25 subjects crossed over to receive spartalizumab.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Spartalizumab 400 mg Q4W</title>
          <description>anti-PD1 humanized monoclonal antibody. Participants treated with spartalizumab who remained on spartalizumab</description>
        </group>
        <group group_id="P2">
          <title>Chemotherapy</title>
          <description>commonly used chemotherapy as per investigator's choice</description>
        </group>
        <group group_id="P3">
          <title>Crossover to Spartalizumab</title>
          <description>Patients treated with Chemotherapy who crossed over to spartalizumab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study : Prior to Cross Over</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>subject / guardian decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>treatment ongoing</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>After Cross Over</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>subject / guardian decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>treatment ongoing</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>There were 122 participants in this trial. Of the 40 subjects from the chemotherapy arm, 25 subjects crossed over to receive spartalizumab.</population>
      <group_list>
        <group group_id="B1">
          <title>Spartalizumab 400 mg Q4W</title>
          <description>anti-PD1 humanized monoclonal antibody. Participants treated with spartalizumab who remained on spartalizumab</description>
        </group>
        <group group_id="B2">
          <title>Chemotherapy</title>
          <description>commonly used chemotherapy as per investigator's choice</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="122"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.1" spread="11.54"/>
                    <measurement group_id="B2" value="50.5" spread="12.32"/>
                    <measurement group_id="B3" value="50.9" spread="11.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival</title>
        <description>Number of Participants with Progression Free Survival at 2 years, as per RECIST v1.1</description>
        <time_frame>2 years</time_frame>
        <population>full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Spartalizumab 400 mg Q4W</title>
            <description>anti-PD1 humanized monoclonal antibody. Participants treated with spartalizumab who remained on spartalizumab</description>
          </group>
          <group group_id="O2">
            <title>Chemotherapy</title>
            <description>commonly used chemotherapy as per investigator's choice</description>
          </group>
          <group group_id="O3">
            <title>Crossover to Spartalizumab</title>
            <description>Patients treated with Chemotherapy who crossed over to spartalizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Number of Participants with Progression Free Survival at 2 years, as per RECIST v1.1</description>
          <population>full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>number of progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>number of deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>number of censored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>evaluate the anti-tumor activity of PDR001 versus investigator choice of chemotherapy in NPC patients</description>
        <time_frame>2 years</time_frame>
        <posting_date>02/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Serum Pharmacokinetics (PK) Parameters</title>
        <description>characterize the pharmacokinetics profiles of PDR001; PK parameters area under the curve (AUC)</description>
        <time_frame>1 year</time_frame>
        <posting_date>02/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence and /or Concentration of Anti-PDR001 Antibodies</title>
        <description>Assess immunogenicity serum concentration</description>
        <time_frame>1 year</time_frame>
        <posting_date>02/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>evaluate the anti-tumor activity of PDR001 versus investigator choice of chemotherapy in NPC patients</description>
        <time_frame>1 year</time_frame>
        <posting_date>02/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR)</title>
        <description>evaluate the anti-tumor activity of PDR001 versus investigator choice of chemotherapy in NPC patients</description>
        <time_frame>1 year</time_frame>
        <posting_date>02/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression (TTP)</title>
        <description>evaluate the anti-tumor activity of PDR001 versus investigator choice of chemotherapy in NPC patients</description>
        <time_frame>1 year</time_frame>
        <posting_date>02/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Related Progression Free Survival (irPFS) Using Central Assessment</title>
        <description>evaluate the anti-tumor activity of PDR001 versus investigator choice of chemotherapy in NPC patients</description>
        <time_frame>2 years</time_frame>
        <posting_date>02/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Concentration vs.Time Profiles</title>
        <description>serum concentration of PDR001 on D1,D8,D15,D29,D36,D43,D57,D58,D64,D71,D85,D140</description>
        <time_frame>1 year</time_frame>
        <posting_date>02/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Potential Associations Between Expression of PD-L1, CD8 and Other Immunological Markers With Anti-tumor Activity</title>
        <description>assess changes in expression of immunological markers such as CD8 and PD-L1 in tumor biopsies</description>
        <time_frame>2 years</time_frame>
        <posting_date>02/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Expression of Immune-related Genes (RNA/Protein in Tumor Sample</title>
        <description>assess changes in immune-related gene signature</description>
        <time_frame>2 years</time_frame>
        <posting_date>02/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peripheral, Soluble Ligands and Cytokine Levels</title>
        <description>assess plasma concentration levels of cytokines interferon-gamma ( IFN-γ) in pg/ml</description>
        <time_frame>2 years</time_frame>
        <posting_date>02/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Serum Pharmacokinetics (PK) Parameters</title>
        <description>characterize the pharmacokinetics profiles of PDR001; PK parameters maximum plasma concentration(Cmax)</description>
        <time_frame>1 year</time_frame>
        <posting_date>02/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Serum Pharmacokinetics (PK) Parameters</title>
        <description>characterize the pharmacokinetics profiles of PDR001; PK parameter as the time to reach maximum peak plasma (Tmax)</description>
        <time_frame>1 year</time_frame>
        <posting_date>02/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Serum Pharmacokinetics (PK) Parameters</title>
        <description>characterize the pharmacokinetics profiles of PDR001; PK parameters include the elimination half-life (T1/2)</description>
        <time_frame>1 year</time_frame>
        <posting_date>02/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peripheral, Soluble Ligands and Cytokine Levels</title>
        <description>assess plasma concentration levels of cytokines as tumor necrosis factor-alpha (TNF-α) in pg/ml</description>
        <time_frame>2 years</time_frame>
        <posting_date>02/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peripheral, Soluble Ligands and Cytokine Levels</title>
        <description>assess plasma concentration levels of cytokines as Interleukin-6 ( IL-6) in pg/ml</description>
        <time_frame>2 years</time_frame>
        <posting_date>02/2022</posting_date>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival - Median PFS</title>
        <time_frame>12 months</time_frame>
        <population>full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Spartalizumab 400 mg Q4W</title>
            <description>anti-PD1 humanized monoclonal antibody. Participants treated with spartalizumab who remained on spartalizumab</description>
          </group>
          <group group_id="O2">
            <title>Chemotherapy</title>
            <description>commonly used chemotherapy as per investigator's choice</description>
          </group>
          <group group_id="O3">
            <title>Crossover to Spartalizumab</title>
            <description>Patients treated with Chemotherapy who crossed over to spartalizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival - Median PFS</title>
          <population>full analysis set</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="1.8" upper_limit="3.6"/>
                    <measurement group_id="O2" value="6.6" lower_limit="3.7" upper_limit="9.3"/>
                    <measurement group_id="O3" value="1.7" lower_limit="1.6" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <desc>Adverse events were collected from first dose of study treatment until end of study treatment plus up to 150 days post treatment, up to maximum duration of 3 years</desc>
      <group_list>
        <group group_id="E1">
          <title>PDR 400mg q4w</title>
          <description>PDR 400mg q4w</description>
        </group>
        <group group_id="E2">
          <title>Chemotherapy</title>
          <description>Chemotherapy</description>
        </group>
        <group group_id="E3">
          <title>Crossover to PDR001</title>
          <description>Crossover to PDR001</description>
        </group>
        <group group_id="E4">
          <title>All PDR001 Subjects</title>
          <description>All PDR001 Subjects</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Normocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Papilloedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Brain abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Electrical burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Bilirubin conjugated increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Blood bilirubin unconjugated increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumour associated fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Diplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (21.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="100" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Interim results cut off 11 OCT 2018</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

